Presently, the domestic IVD market shows a slow overall growth rate, but with the emergence of new projects, the improvement of industry concentration, and the emergence of assembly line trends, etc., the blood coagulation market will become thriving.

The Chinese Society of Laboratory Medicine, China Society of medical laboratory equipment, and Chinese Medical Doctor Association Laboratory Doctor Branch, and other national main secondary testing branches set up special committees or coagulation forums respectively and invite famous domestic and foreign researchers to give special speeches on the relevant progress in the bleeding and coagulation diseases, and conduct academic exchanges in the form of special academic reports and conference speeches, etc., to promote the academic progress of coagulation and the development of the whole coagulation industry.

Implementation of in Vitro Diagnosis of Thrombosis and Hemostasis in the Chinese Market

With the development of the blood coagulation industry, more and more IVD companies have joined it and actively expanded the related services.

In terms of the domestic IVD markets of hemostasis and thrombosis, the special testing items are gradually promoted and popularized in domestic medical institutions.

Coagulation analyzers are mainly applied for laboratory tests of thrombosis and hemostasis, which can provide valuable indicators for the diagnosis and differential diagnosis of hemorrhagic and thrombotic diseases, detection, and efficacy of thrombolytic and anticoagulant therapy.

As indicated by the release of the China Cardiovascular Health and Disease Report 2019, the current number of cardiovascular patients is 330 million and is still on the rise.

Conventional thrombosis and hemostasis diagnostic applications are mainly concentrated on screening for bleeding disorders and diagnosis of bleeding origins, with a relatively narrow scope of application and relatively poor accuracy.

The boundaries between the POCT and laboratory-based systems for blood and electrolyte testing are somewhat blurred, and instruments can be used in multiple scenarios.

Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and informatic solutions, has received FDA clearance for the CN-6000™ Automated Blood Coagulation Analyzer. This clearance includes the reagent products used in five commonly performed hemostasis tests: